MerTK is a mediator of alpha-synuclein fibril uptake by human microglia

Marie-France Dorion1,2,3, Moein Yaqubi2,3, Konstantin Senkevich4,5

  • 1Early Drug Discovery Unit, Montreal Neurological Institute-Hospital, McGill University, Montreal H3A 2B4, Canada.

PubMed

Insights

Mer tyrosine kinase (MerTK) facilitates microglial uptake of alpha-synuclein fibrils, crucial in Parkinson's disease. Targeting MerTK may enhance clearance of these toxic protein aggregates in neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Molecular Biology

Background:

  • Mer tyrosine kinase (MerTK) is vital for microglial cell function in the brain.
  • Its role in clearing protein aggregates in aging and neurodegenerative diseases remains unclear.
  • Alpha-synuclein fibrils are implicated in the pathology of synucleinopathies like Parkinson's disease.

Purpose of the Study:

  • To investigate the function of MerTK in microglial uptake of alpha-synuclein fibrils.
  • To assess the relevance of the MerTK pathway in synucleinopathies.
  • To explore potential therapeutic strategies targeting MerTK for neurodegenerative diseases.

Main Methods:

  • Utilized human primary and induced pluripotent stem cell-derived microglia for in vitro studies.
  • Investigated MerTK-dependence of alpha-synuclein fibril internalization.
  • Conducted burden analysis of MERTK variants and MerTK expression in patient-derived cells and tissues.

Main Results:

  • Pharmacological inhibition and siRNA knockdown of MerTK reduced alpha-synuclein fibril internalization by microglia.
  • MerTK-mediated phagocytosis did not induce pro-inflammatory cytokines and downmodulated IL-1β.
  • Found a significant association between rare MERTK variants and Parkinson's disease in one cohort.

Conclusions:

  • MerTK plays a novel role in mediating human microglial uptake of alpha-synuclein fibrils.
  • This pathway may be involved in limiting alpha-synuclein spread in synucleinopathies.
  • Enhancing MerTK activity could be a therapeutic approach for alpha-synuclein fibril clearance.